A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants [Immunology and Inflammation]
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in over 100 million infections and millions of deaths. Effective vaccines remain the best hope of curtailing SARS-CoV-2 transmission, morbidity, and mortality. The vaccines in current use require cold storage and sophisticated manufacturing capacity, which complicates their...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Novalia Pishesha, Thibault J. Harmand, Paul W. Rothlauf, Patrique Praest, Ryan K. Alexander, Renate van den Doel, Mariel J. Liebeskind, Maria A. Vakaki, Nicholas McCaul, Charlotte Wijne, Elisha Verhaar, William Pinney III, Hailey Heston, Louis-Marie Bloye Tags: Immunology and Inflammation, Coronavirus (COVID-19) Biological Sciences Source Type: research
More News: Academies | Allergy & Immunology | Coronavirus | COVID-19 | Pandemics | Respiratory Medicine | SARS | Science | Vaccines